Home FDA Approves Mercks NOXAFIL (posaconazole) Injection (18 mg/mL) for Intravenous Use
 

Keywords :   


FDA Approves Mercks NOXAFIL (posaconazole) Injection (18 mg/mL) for Intravenous Use

2014-03-14 18:40:00| Merck.com - Product News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use. Mercks antifungal agent is also marketed as NOXAFIL (100 mg) delayed-release tablets and NOXAFIL (40 mg/mL) oral suspension. Language: English Contact: MerckMedia:Pam Eisele, (267) 305-3558Robert Consalvo, (908) 423-6595orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: use injection fda approves

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
25.11dura ace 32H
25.11 (S)
25.111592 33mm 33mm
25.11 DVD 7
25.11DR4270
25.11A +A act2
25.115 SEED FREEDOM
25.11
More »